Parkinson’s Disease: A new path toward restoring key neurodegenerative functions. Discover our analysis of a clinical trial highlighting a potential molecular mechanism of blarcamesine! (ANAVEX®2-73) Blarcamesine significantly restores functionality in key molecular pathways including Alzheimer’s and Parkinson’s disease, KEM® xAI analysis shows. Cambridge, MA, USA and Paris, France – Ariana Pharma, the leading Al-driven precision medicine company, […]
Pushing the promise of AI designed Precision Medicine Parkinson’s Disease Dementia (PDD) therapy closer to the finish line, Ariana, the AI Drug Development Company and ANAVEX Life Sciences announced positive ANAVEX®2-73 Phase II results.
